Denali Therapeutics, Inc. (DNLI)
24.40
-0.53
(-2.13%)
USD |
NASDAQ |
Aug 26, 11:50
Denali Therapeutics Debt to Equity Ratio : 0.0451 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0451 |
| March 31, 2026 | 0.0432 |
| December 31, 2025 | 0.0417 |
| September 30, 2025 | 0.0479 |
| June 30, 2025 | 0.0453 |
| March 31, 2025 | 0.0433 |
| December 31, 2024 | 0.0442 |
| September 30, 2024 | 0.0398 |
| June 30, 2024 | 0.0351 |
| March 31, 2024 | 0.0347 |
| December 31, 2023 | 0.0507 |
| September 30, 2023 | 0.0482 |
| June 30, 2023 | 0.0468 |
| March 31, 2023 | 0.0591 |
| December 31, 2022 | 0.0579 |
| September 30, 2022 | 0.0765 |
| June 30, 2022 | 0.0694 |
| March 31, 2022 | 0.0684 |
| December 31, 2021 | 0.0665 |
| September 30, 2021 | 0.0645 |
| Date | Value |
|---|---|
| June 30, 2021 | 0.0619 |
| March 31, 2021 | 0.0613 |
| December 31, 2020 | 0.0599 |
| September 30, 2020 | 0.0792 |
| June 30, 2020 | 0.1413 |
| March 31, 2020 | 0.1319 |
| December 31, 2019 | 0.1837 |
| September 30, 2019 | 0.167 |
| June 30, 2019 | 0.1534 |
| March 31, 2019 | 0.1398 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Biogen, Inc. | 0.4433 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.158B |
| Total Liabilities (Quarterly) | 322.78M |
| Shareholders Equity (Quarterly) | 835.18M |
| Current Ratio | 8.369 |
| Net Debt Paydown Yield | 0.05% |